StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC)

Stock analysts at StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note issued to investors on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Several other analysts also recently commented on the company. HC Wainwright reissued a “neutral” rating and issued a $6.60 price objective on shares of Revance Therapeutics in a research note on Friday, November 8th. Mizuho lowered their price target on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research report on Tuesday, December 10th. Barclays cut their price objective on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a report on Monday, December 23rd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. Nine equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $8.39.

Revance Therapeutics Price Performance

RVNC opened at $3.65 on Friday. Revance Therapeutics has a fifty-two week low of $2.30 and a fifty-two week high of $7.56. The firm has a market capitalization of $381.02 million, a PE ratio of -1.89 and a beta of 0.90. The company’s 50-day moving average is $3.49 and its 200 day moving average is $4.52.

Institutional Investors Weigh In On Revance Therapeutics

Hedge funds have recently made changes to their positions in the business. Natixis purchased a new stake in Revance Therapeutics during the fourth quarter worth about $31,000. Two Sigma Securities LLC bought a new position in shares of Revance Therapeutics during the 4th quarter valued at approximately $35,000. Alpine Global Management LLC purchased a new stake in shares of Revance Therapeutics during the 4th quarter worth approximately $37,000. FORA Capital LLC bought a new stake in shares of Revance Therapeutics in the 3rd quarter worth approximately $54,000. Finally, RPO LLC bought a new stake in shares of Revance Therapeutics in the 4th quarter worth approximately $55,000. 97.70% of the stock is currently owned by institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.